Loading clinical trials...
Loading clinical trials...
A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Subjects With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Conditions
Interventions
ABBV-368
Tilsotolimod
+2 more
Locations
26
United States
The University of Chicago Medical Center /ID# 217196
Chicago, Illinois, United States
Norton Cancer Institute /ID# 216179
Louisville, Kentucky, United States
Barbara Ann Karmanos Cancer In /ID# 214050
Detroit, Michigan, United States
Nebraska Methodist Hospital /ID# 215786
Omaha, Nebraska, United States
Atlantic Health System /ID# 216159
Morristown, New Jersey, United States
Roswell Park Comprehensive Cancer Center /ID# 215882
Buffalo, New York, United States
Start Date
January 22, 2020
Primary Completion Date
October 27, 2022
Completion Date
October 27, 2022
Last Updated
February 27, 2023
NCT06898450
NCT07259590
NCT03311477
Lead Sponsor
AbbVie
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions